期刊
DRUG DEVELOPMENT RESEARCH
卷 77, 期 2, 页码 53-72出版社
WILEY
DOI: 10.1002/ddr.21295
关键词
Alzheimer disease; antioxidant; autism; bipolar; butyrate; carnitinoids; epigenetic; histone deacetylase; mitochondrial dysfunction; neurodegenerative; neurodevelopmental; neuropsychiatric disorders; PMX-500; Parkinson disease; schizophrenia; PMX-550
资金
- MitoCure Foundation
- US National Science Foundation
- Auburn University
Neuropsychiatric disorders are a heterogeneous group of conditions that often share underlying mitochondrial dysfunction and biological pathways implicated in their pathogenesis, progression, and treatment. To date, these disorders have proven notoriously resistant to molecular-targeted therapies, and clinical options are relegated to interventional types, which do not address the core symptoms of the disease. In this review, we discuss emerging epigenetic-driven approaches using novel acylcarnitine esters (carnitinoids) that act on master regulators of antioxidant and cytoprotective genes and mitophagic pathways. These carnitinoids are actively transported, mitochondria-localizing, biomimetic coenzyme A surrogates of short-chain fatty acids, which inhibit histone deacetylase and may reinvigorate synaptic plasticity and protect against neuronal damage. We outline these neuroprotective effects in the context of treatment of neuropsychiatric disorders such as autism spectrum disorder and schizophrenia. Drug Dev Res 77 : 53-72, 2016. (c) 2016 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据